The effect of probiotic on uremic toxins and quality of life in chronic hemodialysis patients
- Conditions
- hemodialysis patients.Extracorporeal dialysisZ49.01
- Registration Number
- IRCT20170609034406N4
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Age over 18 years
Begining of hemodialysis from previous 3 months for three times a week
Ability to understand and sign a consent form
Use of biocompatible dialysis membrane
Properly functioning arteriovenous fistula or catheter
Pregnancy and lactation
Use of broad-spectrum antibiotics in the last 3 months or now
Allergy to probiotics
The presence of any chronic, active, uncontrolled or severe chronic inflammatory disease (autoimmune diseases, connective tissue disease, malignancy, HIV, liver disease and pulmonary disease)
The presence of chronic or acute infection in a recent month
Concurrently presence in another trial (drug or supplement)
A history of stroke or myocardial infarction in the last 3 months
Receiving medications which are effective on inflammatory factors (corticosteroids or other immunosuppressive drugs, nonsteroidal anti-inflammatory drugs, contraceptives, pentoxifylline)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum level of Indoxyl Sulphate. Timepoint: Before intervention-At the end of intervention. Method of measurement: ELISA kit.;Serum level of P-cresyl sulphate. Timepoint: Before intervention-At the end of intervention. Method of measurement: ELISA kit.;Serum level of P-cresol. Timepoint: Before intervention-At the end of intervention. Method of measurement: ELISA kit.
- Secondary Outcome Measures
Name Time Method Quality of life. Timepoint: Before intervention-At the end of intervention. Method of measurement: Short form (36) quality of life survey.